Company Overview and News

4
PushPay in trading halt as Crowther sells $108m stake, exits

2018-06-18 nbr.co.nz
PushPay shares remain on a trading halt for a bookbuild to sell co-founder Eliot Crowther's 9.03% stake, valued at $108 million on the company's pre-halt price.
DB NZSTY NZSTF

4
Comment: Five steps to stronger capital markets

2018-06-10 nzherald.co.nz
If the New Zealand economy were a human body, then we can think of capital as the oxygen required to sustain life.
NZSTY NZSTF MSCI

0
Brian Gaynor: The NZX must take stock before it's left behind

2018-06-08 nzherald.co.nz
The World Federation of Exchanges (WFE), which was established in 1961 and is based in London, is the industry association for global stock exchanges and clearing houses.
ASXFF NZSTY ASXFY NZSTF

13
NZX 50 rises to record, led by F&P Healthcare

2018-06-06 nzherald.co.nz
New Zealand shares rose, pushing the S&P/NZX 50 Index to a record, as Fisher & Paykel Healthcare extended its gains and investors picked up stocks that are carrying a dividend payment including Ryman Healthcare, Mainfreight and Arvida Group.
FBU RHCGF NZSTY FBU FCREY RYHTY NZSTF RYM FRCEF SML

0
Mainfreight delivers record result as global reach expands

2018-05-29 nzherald.co.nz
Transport and logistics company Mainfreight has marked its 40th year in business with record full-year sales revenue of $2.62 billion - $2b of which was from overseas operations.
NZSTY NZSTF

1
NZX moving in new directions

2018-05-16 nzherald.co.nz
The future of NZ's capital markets lies in building on our economy's unique strengths and recognising the needs of local success stories — not in trying to match what other markets are doing.
PPL MRNRF PUPKY NZSTY NURPF NZSTF NEU

0
Time for NZ to grow FAANGs

2018-05-16 nzherald.co.nz
Their immense reach and intrusion into people's daily digital lives has sparked a backlash from consumers and regulators concerned about the exploitation of data.
WYN NZSTY NZSTF

0
NZX sells Farmers Weekly back to former owners

2018-05-15 nzherald.co.nz
NZX has sold its rural newspaper Farmers Weekly to its former owners Dean and Cushla Williamson for an undisclosed sum, with the new entity taking on all 15 staff.
NZSTY NZSTF

7
Brian Gaynor: Week brings bad news for the NZX

2018-04-13 nzherald.co.nz
It hasn't been a great week for the NZX, with the delisting of Trilogy International, Happy Valley Milk's decision to list on the ASX and Icebreaker's confirmed purchase price by US apparel giant VF Corp when an NZX listing was a potential alternative.
ASXFF NZSTY ANZLY AIR ASXFY NZSTF ANZFF ANZFY AIZ LGO

7
'Great shame' if Fletcher sold and delisted from NZX, says investment chief

2018-04-13 nzherald.co.nz
New Zealand investors would be much the poorer if Fletcher Building left the NZX, an investment expert said, and although the firm had issues, he does not want to see it follow a string of other businesses leaving our sharemarket.
FBU FBU NZSTY ADBCF ADLDY FCREY NZSTF FRCEF ABC

10
Shares keep falling amid global sell-off

2018-03-26 nzherald.co.nz
New Zealand's S&P/NZX 50 Index fell about 1 per cent for the second straight session, joining a global selloff that started on Wall Street and extended into Asia amid fears of a trade war. Spark NZ, Air New Zealand, Sky Network Television and A2 Milk all fell.
AIR ANZFY AIZ SKT SYKWF NZSTY ANZLY VTHPF NZSTF SKKTY ANZFF GTK SML AUG

10
MARKET CLOSE: NZ shares join global sell-off

2018-03-26 nbr.co.nz
(BusinessDesk) - New Zealand's S&P/NZX 50 Index fell about 1 percent for the second straight session, joining a global selloff that started on Wall Street and extended into Asia amid fears of a trade war. Spark NZ, Air New Zealand, Sky Network Television and A2 Milk all fell.
AIR ANZFY AIZ SKT SYKWF NZSTY ANZLY VTHPF NZSTF SKKTY ANZFF GTK SML AUG

16
MARKET CLOSE: NZ shares drop 1% on global selloff, US stocks wobble as Trump backs down on spending bill

2018-03-23 nbr.co.nz
New Zealand's NZX 50 Index dropped nearly 1 percent on global trade news in Friday trading., with Synlait Milk and Sky Network Television suffering while CBL remained in a trading halt as its administrators gained more time to consider its finances.
AIA WBC WEBNF WBK ACKDF AUKNY SKT GNE SYKWF NZSTY AIA WBC NZSTF SKKTY GNE MEZ GEL SML

16
Shares drop 1% on global selloff, led by Synlait, Sky TV

2018-03-23 nzherald.co.nz
New Zealand's NZX 50 Index dropped nearly 1 per cent on global trade news, with Synlait Milk and Sky Network Television suffering while CBL remained in a trading halt as its administrators gained more time to consider its finances.
AIA WBC WEBNF WBK ACKDF AUKNY SKT GNE SYKWF NZSTY AIA WBC NZSTF SKKTY GNE MEZ GEL SML

11
Synlait Milk drives sharemarket to record high

2018-03-21 nzherald.co.nz
New Zealand's S&P/NZX 50 Index rose to a record led by Synlait Milk, which jumped to an all-time high after posting strong first-half earnings growth. Synlait's partner A2 Milk Co also gained, along with Kathmandu Holdings and the Fonterra Shareholders' Fund.
KTHDY BGR NZSTY ANZLY AIR NZSTF ANZFF ANZFY KMD AIZ SML KMD

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...